Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception

Wanichsetakul, Preecha; Kamudhamas, Atiwut; Watanaruangkovit, P.; Siripakarn, Yaowapha; Visutakul, Pachara

doi:10.1016/s0010-7824(02)00308-6

Cited by 53 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten (three cohort, [16][17][18] seven cross sectional [19][20][21][22][23][24][25] ) showed a positive effect, 29 (four RCTs, [26][27][28][29] nine cohort, 30-38 15 cross sectional, [39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] one case series 54 ) showed no effect, and seven (four cohort, [55][56][57][58] three cross sectional [59][60][61] ) showed a negative effect. All of the RCTs showed no effect on BMD, as measured by either dual energy x ray absorptiometry (DXA) 26 27 29 or quantitative computed tomography.…”

Section: Healthy Premenopausal Womenmentioning

confidence: 99%

Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review

2005

View full text Add to dashboard Cite

Seventy five articles on the effect of oral contraceptives and other hormone replacement on bone density in premenopausal and perimenopausal women were reviewed. The evidence was appraised using the Oxford Centre for Evidence-Based Medicine levels of evidence. There is good evidence for a positive effect of oral contraceptives on bone density in perimenopausal women, and fair evidence for a positive effect in ''hypothalamic'' oligo/amenorrhoeic premenopausal women. There is limited evidence for a positive effect in healthy and anorexic premenopausal women. In hypothalamic oligo/ amenorrhoeic women, baseline bone density has been shown to be significantly lower than that in healthy controls, therefore the decision to treat is clinically more important. The ideal formulation(s) and duration of treatment remain to be determined by further longitudinal and prospective randomised controlled trials in larger subject populations.

show abstract

Section: Healthy Premenopausal Womenmentioning

confidence: 99%

Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review

2005

View full text Add to dashboard Cite

show abstract

“…In long-term users, there is an increase in bone mineral density and a significant reduction in the risk of hip fracture after the menopause 36,37 . One recently published crosssectional study, however, has failed to identify a beneficial change in bone mineral density with use of the COC 38 . For women with premature menopause, use of the COC may be more acceptable than using hormone replacement therapy (HRT).…”

Section: Hormonal Methods Combined Oral Contraceptivesmentioning

confidence: 99%

Contraception for the older woman: an update

Bhathena¹,

Guillebaud

2006

Climacteric

View full text Add to dashboard Cite

Although fertility declines with advancing age as the woman approaches the menopause, some risk of pregnancy persists, and effective contraception needs to be offered to avoid an unintended pregnancy. An older woman may have menstrual dysfunction or climacteric symptoms and these factors would need consideration when making the choice of contraception. Low-estrogen dose combined oral contraceptives may be prescribed to healthy non-smoking women up to about 50 years of age. The progestogen-only pill may be an appropriate option in an older woman with declining fertility. The copper intrauterine device is an optimal method for parous women free of pre-existing menstrual problems. The levonorgestrel-releasing intrauterine system is considered the contraceptive method of choice for perimenopausal women with menstrual dysfunction. The woman should be provided with individualized advice so that she has a choice between the newer, effective, largely safe, reversible methods and sterilization.

show abstract

“…Women using combined oral contraceptive pills (COCPs) were included in the control group because there is good evidence it has no effect on BMD in estrogen-replete adult women (8,13,16,19,21,26), and it is the most prevalent contraceptive choice in young women (39), so to exclude users would result in a biased sample. However, COCP use may be associated with a decrease in markers of bone turnover (40,41), so COCP users were excluded from the comparison of bone turnover.…”

Section: Subjectsmentioning

confidence: 99%

“…Studies that have examined the forearm have failed to consistently demonstrate an effect of DMPA on BMD when measured by dualenergy x-ray absorptiometry (DXA) or peripheral quantitative computed tomography (pQCT) (16 -20). Only one study has measured BMD at the forearm and axial skeleton (21). DMPA users had lower BMD than controls at the lumbar spine but no difference at the hip or distal forearm, suggesting that there may be a site-specific effect.…”

mentioning

confidence: 99%

Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study

Walsh

Eastell

Peel

2008

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception

Cited by 53 publications

References 19 publications

Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review

Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review

Contraception for the older woman: an update

Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study

Contact Info

Product

Resources

About